Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

beta-Blocker therapy in heart failure.

R N Doughty1

  • 1Department of Medicine, School of Medicine, The University of Auckland, Auckland, New Zealand.

Heart Failure Monitor
|March 14, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

VEGF-A cis-located SNPs on human chromosome 6 associated with VEGF-A plasma levels and survival in a coronary disease cohort.

BMC cardiovascular disorders·2025
Same author

Prognostic significance of anaemia in patients with heart failure with preserved and reduced ejection fraction: results from the MAGGIC individual patient data meta-analysis.

QJM : monthly journal of the Association of Physicians·2015
Same author

Genetic markers of repolarization and arrhythmic events after acute coronary syndromes.

American heart journal·2015
Same author

The obesity paradox in heart failure patients with preserved versus reduced ejection fraction: a meta-analysis of individual patient data.

International journal of obesity (2005)·2013
Same author

Hyperuricaemia and gout in New Zealand rural and urban Māori and non-Māori communities.

Internal medicine journal·2013
Same author

Genetic variation in the renin-angiotensin-aldosterone system is associated with cardiovascular risk factors and early mortality in established coronary heart disease.

Journal of human hypertension·2012
Same journal

Women, men and heart failure: a review.

Heart failure monitor·2008
Same journal

Anemia and erythropoietin in heart failure.

Heart failure monitor·2008
Same journal

The pharmacological rationale behind polypharmacy in heart failure.

Heart failure monitor·2008
Same journal

Diuretics - a panacea for acute heart failure? Different formulations, doses, and combinations.

Heart failure monitor·2008
Same journal

Congenital heart disease and heart failure.

Heart failure monitor·2008
Same journal

Neuregulin-1 and its potential role in the control of cardiac function.

Heart failure monitor·2008
See all related articles

Beta-blockers offer significant survival benefits for heart failure patients, complementing angiotensin-converting enzyme (ACE) inhibitors. Careful patient selection and dose titration are crucial for safe and effective beta-blocker therapy in chronic heart failure management.

Area of Science:

  • Cardiology
  • Pharmacology
  • Public Health

Background:

  • Heart failure presents a significant public health challenge with high morbidity and mortality, even with current treatments like angiotensin-converting enzyme (ACE) inhibitors.
  • Numerous clinical trials have investigated the role of beta-blockers in heart failure management.
  • Recent large-scale trials confirm substantial survival benefits of beta-blockers, which are additive to ACE inhibitor therapy.

Purpose of the Study:

  • To establish beta-blocker therapy as a key component of standard heart failure treatment.
  • To guide the translation of randomized controlled trial findings into clinical practice for beta-blocker use.
  • To outline patient selection criteria for safe and effective beta-blockade in heart failure.

Main Methods:

Related Experiment Videos

  • Review of large-scale clinical trials on beta-blocker efficacy in heart failure.
  • Analysis of patient characteristics suitable for beta-blocker therapy, including those with mild-moderate heart failure and stable conditions on existing treatments.
  • Examination of specific beta-blocker agents (bisoprolol, carvedilol, metoprolol) demonstrating survival benefits.

Main Results:

  • Beta-blocker therapy provides significant survival benefits in heart failure patients.
  • These benefits are additive to those achieved with angiotensin-converting enzyme (ACE) inhibitors.
  • Survival benefits have been confirmed for bisoprolol, carvedilol, and metoprolol.

Conclusions:

  • Beta-blocker therapy is now an essential part of standard heart failure treatment.
  • Careful patient selection, including those with mild-moderate heart failure and stable on ACE inhibitors and diuretics, is key for safe initiation.
  • Initiation should involve low doses, gradual titration, and close monitoring for adverse effects like hypotension or worsening congestion to ensure safe and effective use.